Royal Bank Of Canada Bristol Myers Squibb CO Call Options Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $46,475 - $27.5 Million	-357,500 Reduced 84.62%	65,000 $4.62 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $129 Million - $142 Million	-1,771,300 Reduced 80.74%	422,500 $32.5 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $66.9 Million - $80.2 Million	1,088,000 Added 98.39%	2,193,800 $160 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $59.3 Million - $69.1 Million	1,105,800 New	1,105,800 $68.9 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.